Screening for Fibrosis in MASLD

What is the current role of imaging in screening for fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD)? Gastrointestinal Imaging Senior Editor Federica Vernuccio, MD, PhD, speaks with Claude Sirlin, MD, about his team's review on evidence-based screening strategies, quantitative imaging techniques, and emerging developments shaping the future of fibrosis assessment in MASLD. Full article: Screening for Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: Evidence, Challenges, and the Role of Imaging—From the AJR Special Series on Screening Key Takeaways Patients with MASLD are at increased risk for cardiometabolic conditions: For most patients with MASLD, these conditions will have the most important impact on their health and well-being. Patients with MASLD face severe complications: These patients need to be identified through screening for referral and individualized treatment. Radiologists should understand their role is growing: As MASLD becomes more prevalent, radiologists will play an increasingly important role in interpretation, characterization, and management of this disease. *Chapters 00:00 - Welcome 00:46 - Why Fibrosis Matters 04:48 - Who to Screen 06:37 - Two Step Screening 09:07 - Choosing Imaging Tools 16:12 - Reporting and Cutoffs 19:18 - Future Innovations Ahead 22:35 - Key Takeaways 24:54 - Closing Thanks Follow AJR on Social Media LinkedIn: https://www.linkedin.com/showcase/ajr-radiology/ YouTube: https://www.youtube.com/channel/UCfFAYezkLMxJGMgIJLN0Dpg Instagram: https://www.instagram.com/ajr_radiology/ TikTok: https://www.tiktok.com/@ajr_radiology X: https://x.com/AJR_Radiology BlueSky: https://bsky.app/profile/ajrradiology.bsky.social Threads: https://www.threads.com/@ajr_radiology *This section was generated using artificial intelligence (Descript) and then reviewed for accuracy.